[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editor's Correspondence
Octomber 12, 2009

Adverse Events in Patients Receiving Cholinesterase Inhibitors Due to Dissimilar Follow-up Periods

Arch Intern Med. 2009;169(18):1718-1725. doi:10.1001/archinternmed.2009.347

The study by Gill et al1 suggested a higher risk of adverse outcomes including syncope, bradycardia, pacemaker insertions, and hip fractures in community-dwelling adults with dementia receiving cholinesterase inhibitors compared with well-matched controls. These findings have important implications, as the agents in question remain the mainstay of symptomatic treatment for an otherwise debilitating illness.